The content and views expressed herein are solely the responsibility of the authors and do not necessarily represent the official views of the University of Texas Southwestern Clinical and Translational Alliance for Research (UT-STAR), the University of Texas Southwestern Medical Center at Dallas and its affiliated academic and health care centers, the National Center for Research Resources, or the National Institutes of Health.
Comparison of Outcomes in Adults With Pediatric-Onset Morphea and Those With Adult-Onset Morphea: A Cross-Sectional Study From the Morphea in Adults and Children Cohort†
Article first published online: 25 NOV 2014
Copyright © 2014 by the American College of Rheumatology
Arthritis & Rheumatology
Volume 66, Issue 12, pages 3496–3504, December 2014
How to Cite
Condie, D., Grabell, D. and Jacobe, H. (2014), Comparison of Outcomes in Adults With Pediatric-Onset Morphea and Those With Adult-Onset Morphea: A Cross-Sectional Study From the Morphea in Adults and Children Cohort. Arthritis & Rheumatology, 66: 3496–3504. doi: 10.1002/art.38853
- Issue published online: 25 NOV 2014
- Article first published online: 25 NOV 2014
- Accepted manuscript online: 22 AUG 2014 10:26AM EST
- Manuscript Accepted: 14 AUG 2014
- Manuscript Received: 17 MAR 2014
- NIH. Grant Number: K23-AR-056303-5
- NIH/National Center for Research Resources/National Center for Advancing Translational Sciences. Grant Number: UL1-TR-000451
Few studies have examined outcomes in adults with pediatric-onset morphea. The objective of the present study was to compare clinical outcomes and health-related quality of life (HRQOL) in adults with onset of morphea in childhood to those in patients with adult onset of morphea.
Participants in the study were drawn from the Morphea in Adults and Children cohort and included 68 adults with pediatric-onset morphea and 234 patients with adult-onset morphea. Outcome measures included the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT), physical examination findings, and HRQOL questionnaires.
Adults with pediatric-onset morphea were younger, had longer disease duration, and were more likely to have the linear subtype of morphea. Patients with pediatric-onset disease were less likely to have active disease. Among patients with active disease, those with pediatric-onset morphea had less disease activity as measured by the LoSCAT. Patients with pediatric-onset disease had higher severity of disease damage when measured by the physician's global assessment of damage, but had similar levels of disease damage when measured by the Localized Scleroderma Skin Damage Index. Patients with pediatric-onset disease had more favorable HRQOL scores for all measures, all of which were statistically significantly different from those in patients with adult-onset morphea.
Adults with pediatric-onset morphea differ from patients with adult-onset disease with respect to disease subtype, severity of disease activity and damage, and levels of HRQOL.